Online Medical Reference

Carotid Artery Stenosis

Natalie S. Evans, MD

Published: May 2016

Definition

Carotid artery stenosis (CAS), atherosclerotic narrowing of the extracranial carotid arteries, is clinically significant because CAS is a risk factor for ischemic stroke, which affects more than 600,000 American adults each year. Ischemic stroke accounts for the vast majority of strokes, and atherothrombosis of large arteries including the carotids cause about 15% of all ischemic strokes.1 The definition of hemodynamically significant CAS varies from study to study ranging in degree of stenosis from 50% to 70% and greater. The U.S. Preventive Services Task Force considers CAS of 60% to 99% to be clinically relevant.2 Carotid intima-media thickness (CIMT), a measurement of the intimal and medial layers of the carotid artery walls, is used to detect early atherosclerotic disease.Increased CIMT is associated with risk of myocardial infarction and stroke, but whether its use results in measurable health benefits remains unclear.3

Back to Top

Risk Factors and Epidemiology

The risk factors for CAS are similar to those for atherosclerosis in other vascular beds: advanced age, tobacco smoking, hyperlipidemia, hypertension, diabetes, and physical inactivity. The prevalence of CAS is slightly higher in men than women.4

Hypertension is a strong risk factor for CAS. In the Systolic Hypertension in the Elderly Program study, systolic blood pressure greater than 160 mm Hg was the strongest independent predictor of CAS.5 The Framingham Heart Study showed twice the risk for CAS of 25% or greater for every 20 mm Hg elevation in systolic blood pressure.6

Smokers are more likely than non-smokers to have significant CAS.7,8 Current smokers are more likely to have significant CAS compared with former smokers and the degree of stenosis is associated with the number of cigarettes smoked over time.6,9

The association between elevated blood cholesterol levels and ischemic stroke is not as strong as that of cholesterol and myocardial infarction (MI) with large epidemiologic studies showing mixed results. Nevertheless, hypercholesterolemia was associated with CAS in the Framingham Heart Study and with carotid atherosclerosis as reflected by carotid intima-media thickness (IMT) in several other studies.6,10-12

Diabetes is associated both with carotid IMT and CAS and their progression.13-18 About 1% of asymptomatic persons 65 years of age and older are estimated to have CAS of 60% to 99%.19 In one study, 7% of all first ischemic strokes occurred in patients with CAS of greater than 60%.20

Back to Top

Natural History

Studies suggest that 5% of individuals with CAS of 70% or more will have a stroke within 5 years9 and quality, long-term data beyond 5 years are lacking. Although there are no validated models for predicting stroke in CAS, including risk factors for stroke itself (hypertension, smoking, high blood cholesterol, and diabetes), men, age older than 65 years, and the physically inactive are more likely to have a stroke related to CAS.21 In the Northern Manhattan Study, blacks and Hispanics had more strokes than whites with CAS.20

Back to Top

Pathophysiology

Atherosclerotic carotid disease occurs when lipoprotein accumulates in the intima of the artery and is oxidatively modified. When this occurs, cytokine release ultimately leads to monocyte deposition in the artery wall. These monocytes then transform into foam cells, causing smooth muscle cells to migrate to the intima and form a lipid-laden plaque with a fibrous cap. These plaques tend to occur at arterial branch points. As atherosclerosis progresses, it may completely occlude the artery lumen, or the plaque may rupture, sending thrombus more distally resulting in a transient ischemic attack (TIA) or stroke.

Back to Top

Signs and Symptoms

Carotid artery stenosis may be entirely asymptomatic. Symptoms occur when plaque ruptures and causes an embolism more distally. The type of symptoms depends on where the thromboembolism occurs. Most carotid artery TIAs and strokes occur in the distribution of the middle cerebral artery (MCA), which may lead to contralateral hemiplegia or sensory loss of the lower face or arm and contralateral homonymous hemianopia. A left MCA stroke may cause expressive aphasia. A right MCA stroke may cause unilateral neglect.

Back to Top

Diagnosis

Clinical Diagnosis

The clinical finding of a carotid bruit on auscultation is non-specfic; therefore, hemodynamically significant CAS cannot be determined by physical examination alone.22

Imaging

Of the imaging modalities available for diagnosis of CAS, duplex ultrasound (DUS) is often used because it requires no radiation or intravenous contrast and is relatively inexpensive compared with computed tomography and magnetic resonance angiography (Figure 1). Duplex ultrasound uses blood velocity to determine the presence and severity of stenosis in conjunction with B-mode grayscale imaging of plaque. There are many velocity criteria for determining degree of stenosis, some more widely accepted than others. The Society of Radiologists in Ultrasound (SRU) consensus criteria defines critical stenosis (greater than 70%) as a peak systolic velocity greater than 230 cm/s along with an end diastolic velocity greater than 100 cm/s and an internal carotid artery to common carotid artery ratio greater than 4.0 (Table 1).23 Peak systolic velocity greater than 125 cm/s but less than the criteria for critical stenosis constitutes 50% to 69% stenosis. The accrediting organization for vascular laboratories, recently recommended that laboratories without rigorously validated internal criteria use the SRU criteria.24

Table 1. Society of Radiologists in Ultrasound Consensus Criteria for Carotid Stenosis23
Primary parameters

Secondary parameters

Degree of stenosis, % ICA PSV, cm/sec Plaque estimate, %* ICA/CCA PSV ratio ICA EDV, cm/sec
Normal <125 None <2.0 <40
<50 <125 <50 <2.0 <40
50-69 125-230 ≥50 2.0-4.0 40-100
≥70 but less than near occlusion >230 ≥50 >4.0 >100
Near occlusion High, low, or undetectable Visible Variable Variable
Total occlusion Undetectable Visible, no detectable lumen Not applicable Not applicable

* Plaque estimate (diameter reduction) with gray-scale and color Doppler ultrasound.

CCA = common carotid artery; EDV = end diastolic velocity; ICA = internal carotid artery; PSV = peak systolic velocity.

From Grant E G, Benson C B, Moneta G L, et al. Carotid artery stenosis: Gray-scale and Doppler US diagnosis—Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-346. Copyright ©2003 by Radiological Society of North America (RSNA). Reprinted by permission of RSNA.

The main disadvantage of DUS is that very tight stenosis may be interpreted as total occlusion, which is problematic because total occlusions cannot be revascularized. Additionally, DUS may overestimate the degree of stenosis compared with digital subtraction angiography, the gold standard,25,26 and the accuracy of the test depends on the operator.27 Nevertheless, the sensitivity and specificity when compared with angiography for detecting stenosis 70% or greater ranges from 85% to 90%.28-30

Computed tomography angiography (CTA) allows imaging of the carotid arteries from the aortic arch to the circle of Willis with 100% sensitivity and 63% specificity (Figure 2). Disadvantages of CTA include use of iodinated contrast, which may be contraindicated in patients with renal insufficiency, and radiation exposure. As with ultrasound, it may be difficult to differentiate a sub-total from a total occlusion with CTA and the degree of CAS may be overestimated.31 Images may also be subject to artifact from metal dental work and heavily calcified plaques.

Similarly, magnetic resonance angiography (MRA) allows imaging from the aortic arch to the brain with sensitivity approaching 100% and specificity of 82% to 95%32-36 and has the advantage of no radiation exposure.37 Contrast-enhanced MRA is superior to non-enhanced MRA in evaluating the carotid arteries but as with CTA, patients with renal insufficiency are not good candidates for contrast-enhanced MRA and MRA may overestimate the degree of stenosis. Individuals with pacemakers and other implants may not be able to undergo MRA.

Conventional catheter angiography is the gold standard imaging modality to which non-invasive imaging techniques have been compared, although its use today is often reserved for cases of diagnostic uncertainty and those in which catheter-based revascularization is planned. In the major endarterectomy trials, different methods of measuring the degree of stenosis were used, although the method used in the North American Symptomatic Carotid Endarterectomy Trial (NASCET) is probably the most widely accepted, in which the residual lumen of the stenotic segment is compared with the normal distal ICA.1 The advantages of catheter angiography over CTA and MRA are that small amounts of contrast may be used and images are not subject to artifact from metal implants or calcium deposits. The major disadvantage is the small risk of stroke, typically less than 1% with experienced operators.38-46

Box 1. Imaging Modalities for Diagnosis of Carotid Artery Stenosis
Advantages Disadvantages
Duplex ultrasound Relatively inexpensive
Non-invasive
No radiation or contrast
Tight stenosis may be interpreted as total occlusion
May overestimate degree of stenosis
Operator-dependent
Computed tomographic angiography Non-invasive
Complete imaging of carotid arteries
Radiation
Need for iodinated contrast
Tight stenosis may be interpreted as total occlusion
Artifact from dental work, metal implants, calcification
Magnetic resonance angiography Non-invasive
Complete imaging of carotid arteries
No radiation
Need for contrast
May overestimate degree of stenosis
Usually contraindicated in patients with pacemakers, other metal implants
Conventional angiography Gold standard imaging Invasive test
Small risk of stroke
Practice Guidelines for imaging

Guidelines issued in 2011 by the American Heart Association (AHA), American Stroke Association, and other bodies recommend DUS as the first-line imaging in asymptomatic patients with suspected CAS or a carotid bruit as well as in those with transient neurologic symptoms that are suspected to be ischemic. CTA or MRA are options when DUS is not readily available or when results are equivocal.47 The Society for Vascular Surgery (SVS) guidelines, also issued in 2011, recommend against screening of asymptomatic patients with carotid bruit and no other risk factors for atherosclerosis.48 The U.S. Preventive Services Task Force recommends against screening for CAS in asymptomatic persons.48

Back to Top

Treatment

Medical Treatment

Controlling hypertension

Control of hypertension is critical in preventing stroke.49,50 Although it is clear that uncontrolled hypertension is associated with the development of carotid atherosclerosis, it is less clear whether treatment of hypertension prevents progression of carotid lesions. Antihypertensive therapy has been shown to be beneficial for persons with atherosclerosis but normal blood pressure in the Heart Outcomes Prevention Evaluation Study, in which participants randomized to ramipril had lower incidence of stroke than those on placebo.51 Current practice guidelines recommend treating patients with asymptomatic CAS to a blood pressure less than 140/90 mm Hg, a strong (Class I) recommendation. This recommendation is the same for symptomatic patients outside the hyperacute period, but the optimal blood pressure level remains undefined.47

Smoking cessation

Patients with established CAS should be asked about smoking status at every visit and current smokers should be offered smoking cessation interventions. Current guidelines make no specific recommendations regarding methods of smoking cessation, but options include behavioral interventions, nicotine replacement therapy, bupropion, and varenicline. The Food and Drug administration advises caution in using varenicline in those with known cardiovascular disease, but two recent meta-analyses have shown no significant increase in cardiovascular events.52,53 A third meta-analysis showed a significant increase in cardiovascular events in varenicline users, but the absolute rate of events was low (1% for active-therapy patients, compared with 0.8% for those receiving placebo) and more participants in the placebo group were lost to follow-up.54 Taking these studies as a whole, varenicline, which is highly efficacious compared with other interventions, likely remains an important therapy in helping patients quit smoking.

Box 2. Medical Management of Carotid Stenosis
Antihypertensive agents
Smoking cessation
  • Pharmacotherapy
  • Nicotine replacement
  • Counseling
Cholesterol control
  • Statins
  • Addition of bile-acid sequestrant or niacin as needed
  • Antiplatelet agents
  • Aspirin
  • Aspirin plus dipyridamole
  • Clopidogrel in aspirin-intolerant patients
Diabetes control
Controlling cholesterol

Although there is abundant evidence that reduction of cholesterol reduces the risk of stroke in all patients with atherosclerosis,55-57 there is less evidence for the benefit of statins in stroke prevention in patients with extracranial CAS. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial of patients with carotid atherosclerosis, atorvastatin compared with placebo reduced the risk of stroke by a third and major coronary events by more than 40%.58 Statins also slow the progression of carotid atherosclerosis as measured by IMT.59-61

Current guidelines call for the addition of a bile acid sequestrant or niacin to aid in achieving optimal cholesterol levels, but recent evidence calls the benefit of niacin into question.62,63

Antiplatelet agents

It is unknown whether aspirin prevents stroke in asymptomatic patients with CAS. In patients with prior history of TIA or stroke, aspirin reduces the risk of stroke.64 The combination of aspirin at doses of 75 mg to 162 mg daily plus clopidogrel is no better than aspirin alone in the prevention of stroke65-66 and aspirin (a total of 50 mg daily) plus extended-release dipyridamole is superior to aspirin 50 mg daily.67 Aspirin plus dipyridamole has not been studied compared with the more usual dosing of aspirin (81–325 mg) commonly available in the U.S. There is no benefit to anticoagulation with warfarin in patients with CAS.68

Control of diabetes

It is unclear whether intensive control of blood glucose can reduce stroke risk, but since it reduces MI risk, it is a part of risk modification for those with asymptomatic and symptomatic CAS.

Surgical options

Recommendations on when to intervene surgically or with a catheter-based procedure for CAS depend on the degree of stenosis and whether the patient is symptomatic or asymptomatic. Recommendations for carotid endarterectomy (CEA) in symptomatic patients with greater than 70% stenosis are based on the NASCET and the European Carotid Surgery Trial, both of which compared CEA with best medical therapy at the time, aspirin.69-71 Both trials were initiated before statins were widely available. In NASCET, although stroke and death rates at 30 days were higher in the CEA group than in the non-surgical group, at 2 years CEA patients had much lower rates of stroke (16% vs. 32%). Patients older than 75 had greater benefit.72 Findings in the MRC European Carotid Surgery Trial were similar, with higher rates of stroke and death in the surgery group at 30 days, but lower rates of stroke at 3 years (12% vs. 22%).70,71

Carotid endarterectomy for asymptomatic people was studied in the Asymptomatic Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial (ACST). Again, best medical therapy at the time was aspirin. The ACAS and ACST trials randomized participants with 60% to 99% stenosis to CEA or aspirin. The ACAS trial showed about half the rates of ipsilateral stroke in the CEA group at 3 years, 5% compared with 11%.73 Rates of stroke in the ACST trial were also about half at 3 years in the CEA group, 6% vs. 12%.74 In this trial, men appeared to benefit more than women, and the benefit in patients older than 75 was uncertain, probably due to relatively small numbers of these people in the trial.

Since these trials were performed, carotid artery stenting (CAS) has emerged as an alternative to CEA. The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST), which randomized both symptomatic and asymptomatic patients with carotid atherosclerosis to carotid artery stenting vs. CEA, found no difference in the composite of stroke, MI, or death within 30 days and ipsilateral stroke during long-term follow-up.75 There were more strokes and fewer MIs at 30 days in the carotid artery stenting group, and patients 70 and older had overall better outcomes with CEA. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial randomized "high-risk" patients, including those with previous CEA, to carotid artery stenting vs. CEA. It found that carotid artery stenting was non-inferior to CEA at one year using the composite endpoint of stroke, MI, or death within 30 days and death or ipsilateral stroke within a year. Similar to CREST, older patients in the SAPPHIRE trial did better with CEA.76

Practice guidelines for treatment

The AHA guidelines recommend treating hypertension to maintain blood pressure below 140/90 mm Hg in asymptomatic CAS patients.47 In patients with symptomatic CAS who are outside the hyperacute period, blood pressure probably should be treated, but the benefit of treating to a specific target has not been established in relation to risk of exacerbating cerebral ischemia. All patients with CAS should be encouraged to quit smoking and offered cessation interventions, and all should be treated with a statin to reduce LDL cholesterol below 100 mg/dl, with an optional goal below 70 mg/dl in those with history of ischemic stroke. Similarly, patients with diabetes should be treated to an LDL below 70 mg/dl.

The AHA guidelines also recommend aspirin 75 mg to 325 mg daily for all patients with CAS to lower the risk of MI. Those with a history of ischemic stroke or TIA should get aspirin or aspirin-dipyridamole over aspirin plus clopidogrel. Clopidogrel and ticlopidine are alternatives in those who cannot take aspirin for reasons other than bleeding. Anticoagulation is not recommended unless the patient has another indication such as atrial fibrillation or a mechanical heart valve.

The SVS guidelines recommend that all patients with CAS be treated for hypertension and hypercholesterolemia and offered smoking cessation therapies, along with antiplatelet therapy.48

The AHA recommends CEA for symptomatic patients with average or low surgical risk and stenosis >70% by noninvasive imaging or >50% on catheter angiography. Carotid artery stenting can be used for symptomatic patients with the same degree of stenosis and favorable risks for endovascular intervention, when the anticipated periprocedural stroke and mortality rate is less than 6%. The AHA encourages practitioners to consider individual patient factors including life expectancy in determining which asymptomatic patients should be revascularized.

The SVS recommends medical management only for symptomatic patients with stenosis less than 50% and asymptomatic patients with stenosis less than 60%. The SVS prefers CEA to carotid artery stenting, except possibly in patients younger than 70 years.

Back to Top

Summary

Carotid stenosis is a risk factor for ischemic stroke. Imaging for CAS includes duplex ultrasound, CTA, MRA, and catheter angiography, but ultrasound is usually the preferred initial imaging modality. All patients with CAS should have medical management that includes control of hypertension, cholesterol levels, and diabetes, administration of antiplatelet agents, and smoking cessation. Selection of appropriate patients for revascularization depends on the degree of stenosis and presence or absence of symptoms.

Back to Top

References

  1. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 2000; 342:1693–1700.
  2. Jonas DE, Feltner C, Amick HR, Sheridan S, Zheng ZJ, Watford DJ, et al. Screening for asymptomatic carotid artery stenosis: a systematic review and meta-analysis for the US Preventive Services Task Force. Evidence Synthesis No. 111. AHRQ Publication No. 13-05178- EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
  3. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010; 56:2006–2020.
  4. Mathiesen EB, Joakimsen O, Bonaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study. Cerebrovasc Dis 2001; 12:44–51.
  5. Sutton-Tyrrell K, Alcorn HG, Wolfson SK, Jr., Kelsey SF, Kuller LH. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993; 24:355–361.
  6. Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997; 337:516–522.
  7. Djousse L, Myers RH, Province MA, et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke 2002; 33:1357–1361.
  8. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994; 44:1046–1050.
  9. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992; 23:1752–1760.
  10. O'Leary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996; 27:224–231.
  11. Sacco RL, Roberts JK, Boden-Albala B, et al. Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. The Northern Manhattan Stroke Study. Stroke 1997; 28:929–935.
  12. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994; 14:1098–1104.
  13. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2002; 155:38–47.
  14. Dobs AS, Nieto FJ, Szklo M, Barnes R, Sharrett AR, Ko WJ. Risk factors for popliteal and carotid wall thicknesses in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1999; 150:1055–1067.
  15. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999; 22:1077–1083.
  16. Haffner SM, Agostino RD, Jr., Saad MF, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000; 85:1395–1400.
  17. Wagenknecht LE, D'Agostino R, Jr., Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28:999–1005.
  18. Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003; 23:1035–1041.
  19. Wolff T, Guirguis-Blake J, Miller T, Gillespie M, Harris R. Screening for carotid artery stenosis: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 147:860–870.
  20. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005; 111:1327–1331.
  21. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:517–584.
  22. Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits and cerebrovascular disease risk: a meta-analysis. Stroke 2010; 41:2295–2302.
  23. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis--Society of Radiologists in Ultrasound consensus conference. Radiology 2003; 229:340–346.
  24. Intersocietal Accreditation Commission Vascular Testing. IAC vascular testing white paper on carotid stenosis interpretation criteria. January 2014. intersocietal.org/vascular/main/links_references.htm. Accessed November 11, 2015.
  25. Nederkoorn PJ, Mali WP, Eikelboom BC, et al. Preoperative diagnosis of carotid artery stenosis: accuracy of noninvasive testing. Stroke 2002; 33:2003–2008.
  26. Sabeti S, Schillinger M, Mlekusch W, et al. Quantification of internal carotid artery stenosis with duplex US: comparative analysis of different flow velocity criteria. Radiology 2004; 232:431–439.
  27. Zwiebel WJ. Duplex sonography of the cerebral arteries: efficacy, limitations, and indications. AJR Am J Roentgenol 1992; 158:29–36.
  28. Jahromi AS, Cina CS, Liu Y, Clase CM. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg 2005; 41:962–972
  29. Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. Stroke 2003; 34:1324–1332.
  30. Utter GH, Hollingworth W, Hallam DK, Jarvik JG, Jurkovich GJ. Sixteen-slice CT angiography in patients with suspected blunt carotid and vertebral artery injuries. J Am Coll Surg 2006; 203:838–848.
  31. Chappell FM, Wardlaw JM, Young GR, et al. Carotid artery stenosis: accuracy of noninvasive tests--individual patient data meta-analysis. Radiology 2009; 251:493–502.
  32. Alvarez-Linera J, Benito-Leon J, Escribano J, Campollo J, Gesto R. Prospective evaluation of carotid artery stenosis: elliptic centric contrast-enhanced MR angiography and spiral CT angiography compared with digital subtraction angiography. AJNR Am J Neuroradiol 2003; 24:1012–1019.
  33. Cosottini M, Pingitore A, Puglioli M, et al. Contrast-enhanced three-dimensional magnetic resonance angiography of atherosclerotic internal carotid stenosis as the noninvasive imaging modality in revascularization decision making. Stroke 2003; 34:660–664.
  34. Remonda L, Senn P, Barth A, Arnold M, Lovblad KO, Schroth G. Contrast-enhanced 3D MR angiography of the carotid artery: comparison with conventional digital subtraction angiography. AJNR Am J Neuroradiol 2002; 23:213–219.
  35. Wutke R, Lang W, Fellner C, et al. High-resolution, contrast-enhanced magnetic resonance angiography with elliptical centric k-space ordering of supra-aortic arteries compared with selective X-ray angiography. Stroke 2002; 33:1522–1529.
  36. Yucel EK, Anderson CM, Edelman RR, et al. AHA scientific statement. Magnetic resonance angiography : update on applications for extracranial arteries. Circulation 1999; 100:2284–2301.
  37. Long A, Lepoutre A, Corbillon E, Branchereau A. Critical review of non- or minimally invasive methods (duplex ultrasonography, MR- and CT-angiography) for evaluating stenosis of the proximal internal carotid artery. Eur J Vasc Endovasc Surg 2002; 24:43–52.
  38. Davies KN, Humphrey PR. Complications of cerebral angiography in patients with symptomatic carotid territory ischaemia screened by carotid ultrasound. J Neurol Neurosurg Psychiatry 1993; 56:967–972.
  39. Davies KN, Humphrey PR. Do carotid bruits predict disease of the internal carotid arteries? Postgrad Med J 1994; 70:433–435.
  40. Dion JE, Gates PC, Fox AJ, Barnett HJ, Blom RJ. Clinical events following neuroangiography: a prospective study. Stroke 1987; 18:997–1004.
  41. Earnest F 4th, Forbes G, Sandok BA, et al. Complications of cerebral angiography: prospective assessment of risk. AJR Am J Roentgenol 1984; 142:247–253.
  42. Eisenberg RL, Bank WO, Hedgcock MW. Neurologic complications of angiography for cerebrovascular disease. Neurology 1980; 30:895–897.
  43. Grzyska U, Freitag J, Zeumer H. Selective cerebral intraarterial DSA. Complication rate and control of risk factors. Neuroradiology 1990; 32:296–299.
  44. Hankey GJ, Warlow CP, Molyneux AJ. Complications of cerebral angiography for patients with mild carotid territory ischaemia being considered for carotid endarterectomy. J Neurol Neurosurg Psychiatry 1990; 53:542–548.
  45. Hankey GJ, Warlow CP, Sellar RJ. Cerebral angiographic risk in mild cerebrovascular disease. Stroke 1990; 21:209–222.
  46. Leonardi M, Cenni P, Simonetti L, Raffi L, Battaglia S. Retrospective study of complications arising during cerebral and spinal diagnostic angiography from 1998 to 2003. Interv Neuroradiol 2005; 11:213–221.
  47. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Catheter Cardiovasc Interv 2013; 81:E76–E123.
  48. Ricotta JJ, Aburahma A, Ascher E, Eskandari M, Faries P, Lal BK; Society for Vascular Surgery. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. J Vasc Surg 2011; 54:e1–e31.
  49. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:776–785.
  50. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955–1964.
  51. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145–153.
  52. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.
  53. Ware JH, Vetrovec GW, Miller AB, et al. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther 2013; 20:235–246.
  54. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183:1359–1366.
  55. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902–2909.
  56. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–1278.
  57. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004; 117:596–606.
  58. Sillesen H, Amarenco P, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39:3297–3302.
  59. Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344–1353.
  60. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577–581.
  61. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055–2060.
  62. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203–212.
  63. Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 2014; 371:288–290.
  64. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71–86.
  65. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706–1717.
  66. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331–337.
  67. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neruol Sci 1996; 143:1–13.
  68. Mohr JP, Thompson JL, Lazar RM, et al; Warfarin-Asprin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444–1451.
  69. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325:445–53.
  70. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337:1235–1243.
  71. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379–1387.
  72. Alamowitch S, Eliasziw M, Algra A, Meldrum H, Barnett HJ; North American Symptomatic Carotid Endarterectomy Trial (NASCET). Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001; 357:1154–1160.
  73. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273:1421–1428.
  74. Halliday A, Mansfield A, Marro J, et al; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491–1502.
  75. Brott TG, Hobson RW, 2nd, Howard G, Roubin GS, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11–23.
  76. Yadav JS, Wholey MH, Kuntz RE, et al; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterecomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351:1493–1501.

Back to Top

Disclosures

Natalie S. Evans, MD, no disclosures.

Back to Top